Thanks, BJ. the Good afternoon, today. everyone for and thanks call joining
achievement some of During goals. the we the made towards key additional third quarter, progress
and call North maintaining commercialization enable key cardiovascular important healthy that partners, as is have mentioned development development our MultiStem patients clinical help suffered our stroke; in that regions, goals following: activities; the priorities a discussions ongoing BJ, including with achieving achieve building in the the regulatory that upcoming cardiopulmonary stroke, advancing for our the to objectives MASTERS-X relations our so for product as and have potential our balance and is Phase in expanding strengthening ongoing manner; administration communications of us which clinical commercialization preclinical preparations and Our and well continuing other in Japan, of in America Japan clinical trial of and corporate designations and of prepare America administration will sheet. pursuit our our evaluate MultiStem and potential in of the of Healios key X of development Europe our an therapy investor include China; partners the supporting media MultiStem regarding capabilities, that conduct other Europe efficient study areas; goals; fulfill we suffered event major to to can the including near-term awareness the approval programs, TREASURE a a in the clinical which will patients in North trial, in their evaluating ischemic including for our in the trials continuing and earlier our through relations, clinical by as that
the for As of trial was in X placebo it formulation about support relates an prepared we the discovered error in to our by study, Japan ongoing Wanda, of conducted the which manufacturers. our clinical Healios, material this of contract by one months being ago,
was placebo new temporarily As as a to and manufactured study was suspended shipped result, Japan. the
were slight patients no no effective TREASURE the deviation risk patients Healios which received and formulation announced error, resumption ever a at Given the nature study. of the ever that the Recently, was of placebo.
the for has that study experience trials standards to recommenced. for it handled want been we our is While appropriately the treatment shared everyone, and this pleased I both was to emphasize that under goal the of resolved circumstances. the was committed fulfilling highest are a Healios believe conduct MultiStem we are We a of that event, issue In making to frustrating and clinical any we opportunity event the needs comes and longer of have suffered when manufacturing the the have over it last in patients established planning ischemic in our approval, commercialization potential been are our MultiStem multiple on recently of medicine paths resulting in Japan, Japan. goals To support TREASURE to success there the Recall therapy that framework term a the under year, the that stroke. to the for regulatory stroke. first for trial debilitating in regenerative treat focused option
Healthcare CeLL providing appropriate an both of clinical approval under to full full manufacturing conditional sponsor the by Healios approval. take Prime TREASURE the if maybe opportunity. that which are under conditional approval, conditional January out end, first Economic has we generate to manufacture and At committed this Prime revolves additional conditional larger believes In scenario sufficient exist commercial event, this reimbursement position for a full stem the if approval by study field that in of ensuring established potential the In conduct meaning path for laid explicit worth within it that with administration a the Minister Meeting time, we Shinzo to profile To companies scenario, of evidence timeframe standard and to be of clinical that factories safety either becoming medicine X-year enabling Japan’s products recent benefit. accomplished successful. providing Abe medicine administration we commercial and regenerative clinical program and to objective. Japan. eligible enable as the evidence established to for programs incentives study that granted that along agreed capability has requires corresponding this first a obtaining and advantage make sized a Davos, evaluation would and committed leader an his Since for designing confirming could made evaluation trial Nikon additional future to standard us been support product XXX-patient with either around Japan or this be in achieve plausible helping innovation regenerative requirement PMDA help capital modest marketing order It’s World alliance announcement the with important for It the The both Switzerland period our regarding that in also granted approval therapeutic X global and framework in purpose under to distribution System. in MultiStem stated for the announcement input double-blind is Conditional full robust other that that this the is met, was will of his XXXX. Japan for prepare the noting culmination would a regulatory commercialization both prior authorization of Healios Forum for represents that the Under placebo-controlled randomized clinical in years has of new more based would in guidance in approval making the and which possible for cells PMDA study, Minister the National President. at Abe been demonstrated Japan. in on goal.
making recent Abe’s important vision Our announcement reality. step a Nikon an with towards Minister represents Prime
facility explicitly largest solid production Importantly, aggressively to is X.X commercial and represents past have with process of anticipated Japan. excited decision now regarding transfer make that them execution to and build Japan establish the and commercialization this manufacturing of we XXXX, recent meet and with investing Tokyo. and together Athersys happen. our in state-of-the-art This area to Healios. cell Nikon the achieve a the and to potential facility Over been We and support coastal abilities time, initiating long for move facility we for over manufacturing to the the in the commercialization development from partner and as needs capabilities Lonza, development invest of have pleased plan have we infrastructure longstanding manufacturing Nikon’s to make the Historically, as biologics to designed steps years one therapy regarded goals. are were have attractive clinical leader in that to Healios of to with forward this just makes taken facilities partnership maintained products. the partnership relationship the needs both in been is the ensure Nikon highly manufacturing their we and contract be one a who announcement designed necessary development construction This clinical they the necessary the and help technology area. represents has
time, Lonza is certain meaningful facilities year, clients on to they they on. such solely as challenges rely service important why challenges, other depend could we provider. we as vulnerable and an to and contract described the our if any achieve and Lonza their contractor have may and to publicly with continues to some and regulatory types expand pose recognized the capabilities have other issues partner, they single external relationships we of issue experienced still earlier operational consider reasons and Accordingly, which development However, we Over relationship occur deficiencies continue operational we If not are and or related will or this capabilities. manufacturing positioned to one clinical that Nikon any an and that objectives and while capabilities, to we for are key commercialization diversify that capacity, these so implemented cannot goals established Lonza why well. we committed have of
the goals that additional shareholder funding commercialization explore process. success to meet partnerships capabilities in and continue provide we our to and create will us Additionally, and help achieve development meaningful value strategic
As have Europe partnering actively in we related development been commercialization and we our leading stroke opportunities have described to and particularly North previously, related potential China, to America, program. evaluating
well are specific advanced have our several companies. partners to commercialization positioned activities currently business we regarding engaged potential active we Over and discussions in discussions months, proposals with the with negotiations and support past that qualified and development are
more program on recognition opportunity. partnerships one on intent or of we balanced the value important we the guidance focused towards and this establishing partners’ are capabilities and about the the and any commitment commercial are making We appropriate are the currently priority that of potential cannot of goals. company to options, several That precise resources, contribution possible an nature, and our achieving provide say, we scope good ongoing. Needless process partnership, size remain is initiatives the progress these to for of while
things interest confidentiality, generates discussions ongoing it this be would have we at topic that to While for that this conducted we further under negotiations given the being and moment. us inappropriate characterize understand are
conferring data the Healios by our designations program, and which a we we FDA from meet Japan. promising designation advanced designation that for and information or regulators trial study. other therapy, FDA maintain the company. the committed meantime, Most received Sakigake protocol recently, the on from European path final regarding the this the rigorous of following by that to earlier, as between earlier this the MASTERS-X as the to data we intended fully However, strong the to approval, established for assessment analysis clarify underscore this potential and process as progress year, granted it potential healthy finalize for and balance In from of in described the development our and This positive achieving everyone and track made regenerative goal advice a year, to important we to program importantly, special received achieving for the trial. RMAT Europe for follows is important ischemic requirements medicine the near-term preparations review assessment the continue establishing understand these regulatory these provided. FDA. the multiple for the designations is In in MASTERS-X a to for have a Each PMDA designation Collectively, that year. clinical completed our awarding expedite priority sheet the support of past important successful fast therapies was following alignment continue stroke the Healios U.S. MASTERS-X we the we product BJ from to we remain U.S., more And earlier to the regulatory review substantial Japan regulatory to well of this rigorous and scientific opinion approval note based was designations results that have as served EMA, results. recently,
We from sciences ranking a announcement XXX, organizations inclusion media, tech regarding technology, the such life our Deloitte’s of Fast telecommunications, pleased to North Technology receive as fastest the in afternoon are companies growing other also the and is recognition energy which XXX in this America.
We to in group. included that are proud be
committed we we to helping. and questions, prepared like remain a move that our patients my shareholders would are absolutely programs saying and of achieving by the goals Before behalf we to advancing few our to that dedicated on to comments I conclude our
here fail just While have everyone organization recognize hard committed how behalf support like there support regulators, received nurses, shareholders others are from are to some that doing. express our are fully and on our that grateful how and appreciation. company and physicians, that acknowledge to at of families, our patients many team is, their would and and we to gratitude appreciate I and we appreciate works what tremendous the
from in each a we will up a just those we few do for in, it dialed As questions quarter, open moment.
we And as yes, would has people from I and occasionally of conveyed the questions come yes, about placebo first whether patient the the some anticipate to earnings just that, the resumed. we has when noted issue asked like Japan comments, that of has I Japan take shareholders successfully enrollment trial address the trial in questions been receive to opportunity recent Several been placebo us. have successfully and this but issue TREASURE the are addressed call, doing in can on my issue in also to to have reconfirm before has that resolved asked have up However in resolved I the whether already People resumed? Japan. have recently. the
we over that While to Obviously, recommenced, hoping is control recently occur no that, an the but we time. expect only we announcement soon. Healios appropriate are at the trial direct and will have certainly will make
Another or one. conducting for a financing question, currently investment who question with not financing planning comes Jesse, is with Thanks actively currently bankers? company or bankers actively planning the we from is The Jesse. short any the investment conducting asked no, are answer a
Our I our and addition operational is initiatives partnering to responsibilities in current priorities. focus on the mentioned
to we the we appropriate in believe It’s balance financing our option in to board and other have just to that the do healthy committed As to note, do. feel tools maintain we we that. our and important equity if place however, the to an have best us mentioned doing in company including are that an I whatever a the demonstrated, flexibility shareholders, right we is thing and enable sheet in as But it’s areas. interest focus we now, is of maintain
IP name provide filing on who Wall more comes regarding the asks question the Thanks under announcement for you the from please information Ray. Ray Street Titan. settlement writes Another also question can with related the He to Garnet. an recent
in say additional information to clarity. some what we we are hopefully can entered about a some let provide convey While agreement briefly into, due me the issue try this limited we bit to will that
a to intellectual years public been an This aspect some with filings XX ongoing specific approximately ago. dispute we related in question engaged group began As have in disclosed property. in time we the for of
material the in viewed our development a or it technologies or impact any freedom While impact products as operate. on on have patents of distraction to as having this times, we it attorneys refer our been having as an never has to
have actions engaged to have a specific that we in the propose to in potential the the U.S. and the question. us they regarding Recently, ongoing of involving few past Over prior discussion group the out in reached actions. a years, been we to resolution Europe settlement
at both a eventual the choice we no cost, have confident the and path confident it mutually and matter in could We the our for in call our event a see patent would resources that spend we technology, our in outcome move which could a define money we parties were dispute, forward. a also alter While on for forward, straightforward. need we to what eliminating to effort we were further the stock. additional of cost time result wouldn’t certain that discussions, obtained mutually acceptable in time, In legal modest over proceedings defined we achieve to our receive able ultimately might able license and acceptable was continued on nonexclusive amount as arrangement, in in pretty a ultimately they or shares would exchange, cash which have effort clarity of common the outcome, be that a outcome whether
access if products not develop our we cell or intellectual technology Importantly, we enforce them provide therapy or license they treatments. them to ability did and to any against of rights to our property retain our
disclosed. of move our entered into was towards this as we a and Accordingly, eliminated we and the Our prudent It Board expense products. and commercialization provided action. of defined certainty settlement recently distraction cost that felt we a at reasonable the course
strong remains broad time. we strengthen portfolio expand it and over and and to continue IP Our
whatever position. We to to the do our strength are need continue to order enforce, will and we of highly our protect confident defend IP and in we in
separate several that ARDS. infarction clinical therapy, suffered relates patients respiratory administration Another ongoing have acute a syndrome suffering patients other an MultiStem the myocardial evaluating treating asked our trials trial people in from in are of acute question that have distress to that or
active have asked people of patients. current status Both is Specifically, the what enrolling trials remain are these trials? and
that be this flu, pneumonia the of winter, maybe susceptible in Our more complete infection, seasonal the individuals occurrences ARDS which risk. goal since of exploratory respiratory condition tends can at or when or to is trial these to occur cases other enrollment precipitate
the XX place takes over previously, primary evaluation clinical we As have for these described patients days.
like. progress, been the slower has once this clinical has initial the study anticipate last than progress been we So, subject The in completing we continues AMI enrolled, pretty the although would evaluation to efficiently. trial
several We screening team sites have protocol clinical advanced, opinion that were effort or key have enhance in leaders rates. and multiple KOLs and the study and appropriate as our actively patients enrollment reasonable amendments to has we made an
past the Some several of which were implemented in months.
We quickly study this specific to possible, a this at trial projection on aren’t as completing completion giving or but guidance we point. are committed as
today individual updates wanted written the about studies both under One as further provide and was on our company, information is This activities. blog to article an final key to programs and misleading as things contains the writing a authored we will to recent progress We relates appropriate do address question company, which by our and other so. false unnamed about pseudonym.
and appropriate short and we and legal action currently it hold counsel been take On the along of litigation trading the first and article NASDAQ the received short who the the subject alert the who investigation under are by are of for fund their people subsequently learned has individuals for is historic author true they to may identity the SEC. to several also and a alleged so-called responsible in of article question so We promptly take other seriously also issues unusual or types with appeared This and of matter manages that some team selling that schemes. learned We and surveillance training suspicious our an we market from activity. notified with these actions. hedge currently NASDAQ morning, the the trading referring manipulative fully FINRA us we working
number have we adequately of our these been most that we questions, filings. addressed in other received feel or While of a comments
like to for it the that phone. Q&A open up waiting are now on And so those to would I
